Where does CV stock trade?

CapsoVision Inc. (CV) is listed on NASDAQ.

What sector and industry is CV in?

CapsoVision Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.

When did CapsoVision Inc. go public?

CapsoVision Inc. (CV) completed its IPO in 2025.

What are analysts saying about CV?

CapsoVision Inc. has had 2 recent analyst actions on file. The most recent action was from The Benchmark Company: Speculative Buy with a $500.00 price target on 2025-07-28. Recent price targets range from $500.00 to $600.00.

What companies are similar to CV?

Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare CV side-by-side with any of them on Quantisnow.

How can I track CV on Quantisnow?

Quantisnow aggregates CapsoVision Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CV to receive live email and push alerts on every new disclosure.

CV

NASDAQ

CapsoVision Inc.

SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusIPO2025

$6.79-0.42 (-5.76%)

News25/Ratings2

News · 26 weeks37-62%

2025-12-142026-06-07

Mix2790d

Insider12(44%)
SEC Filings9(33%)
Earnings3(11%)
Offering2(7%)
Other1(4%)

Latest news

25 items

4dINSIDER
SEC Form 4 filed by Officer Wang Kang-Huai
4 - CapsoVision, Inc (0001378325) (Issuer)
4dINSIDER
SEC Form 4 filed by Sr. VP of Finance Garcia David Michael
4 - CapsoVision, Inc (0001378325) (Issuer)
4dINSIDER
SEC Form 4 filed by Head of Global Sales Atkinson Douglas Patrick
4 - CapsoVision, Inc (0001378325) (Issuer)
24dSEC
SEC Form 10-Q filed by CapsoVision Inc.
10-Q - CapsoVision, Inc (0001378325) (Filer)
24dSEC
CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
8-K - CapsoVision, Inc (0001378325) (Filer)
24dPR
CapsoVision Reports First Quarter 2026 Financial Results
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026. Recent Highlights Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health Systems
32dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by CapsoVision Inc.
SCHEDULE 13G/A - CapsoVision, Inc (0001378325) (Subject)
32dINSIDER
Head of Global Sales Atkinson Douglas Patrick exercised 107,357 shares at a strike of $0.42 (SEC Form 4)
4 - CapsoVision, Inc (0001378325) (Issuer)
38dPR
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 5439091. The live and archived webcast of the
40dSEC
SEC Form DEF 14A filed by CapsoVision Inc.
DEF 14A - CapsoVision, Inc (0001378325) (Filer)
46dSEC
SEC Form EFFECT filed by CapsoVision Inc.
EFFECT - CapsoVision, Inc (0001378325) (Filer)
51dSEC
SEC Form S-1 filed by CapsoVision Inc.
S-1 - CapsoVision, Inc (0001378325) (Filer)
69dINSIDER
SEC Form 3 filed by new insider Shen Ching Hang
3 - CapsoVision, Inc (0001378325) (Issuer)
73dINSIDER
SEC Form 3 filed by new insider Harari Eliyahou Et Al
3 - CapsoVision, Inc (0001378325) (Issuer)
73dSEC
SEC Form 10-K filed by CapsoVision Inc.
10-K - CapsoVision, Inc (0001378325) (Filer)
73dSEC
CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
8-K - CapsoVision, Inc (0001378325) (Filer)
73dPR
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024.CapsoCam Plus® used by over 161,000 patients as of
76dINSIDER
SEC Form 4 filed by Tsai Chen Lung
4 - CapsoVision, Inc (0001378325) (Issuer)
76dINSIDER
SEC Form 4 filed by Kuo Hui Ying
4 - CapsoVision, Inc (0001378325) (Issuer)
76dINSIDER
SEC Form 4 filed by King Wen-Herng Henry
4 - CapsoVision, Inc (0001378325) (Issuer)
76dINSIDER
SEC Form 4 filed by Imperial Joanne Carol
4 - CapsoVision, Inc (0001378325) (Issuer)
76dINSIDER
SEC Form 4 filed by Harari Michele
4 - CapsoVision, Inc (0001378325) (Issuer)
76dINSIDER
SEC Form 4 filed by Gouw Julia S
4 - CapsoVision, Inc (0001378325) (Issuer)
80dSEC
CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Regulation FD Disclosure
8-K - CapsoVision, Inc (0001378325) (Filer)
80dPR
CapsoVision Announces $14 Million Private Placement Financing
SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the "Company") (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private placement in public equity financing (the "Private Placement") pursuant to a securities purchase agreement entered into by the Company with selected accredited investors on March 16, 2026 for such investors to purchase shares (the "Shares") of common stock of the Company. Pursuant to the securities purchase agreement, the Company has agreed to sell 2,867,089 shares of common stock of the Company, with par value $0.001 per

CV FAQ

6 questions

Where does CV stock trade?
CapsoVision Inc. (CV) is listed on NASDAQ.
What sector and industry is CV in?
CapsoVision Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.
When did CapsoVision Inc. go public?
CapsoVision Inc. (CV) completed its IPO in 2025.
What are analysts saying about CV?
CapsoVision Inc. has had 2 recent analyst actions on file. The most recent action was from The Benchmark Company: Speculative Buy with a $500.00 price target on 2025-07-28. Recent price targets range from $500.00 to $600.00.
What companies are similar to CV?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare CV side-by-side with any of them on Quantisnow.
How can I track CV on Quantisnow?
Quantisnow aggregates CapsoVision Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CV to receive live email and push alerts on every new disclosure.